The Independent Effect of Propofol Anesthesia on Whole Body Protein Metabolism in Humans

The study was approved by the Hospital Ethical Committee and informed consent was obtained from all patients. Six patients (four men, two women) of mean age of 43 yr (range, 25-64 yr), mean body weight of 70 kg (range, 51-84 kg), and mean height of 170 cm (range, 154-180 cm) with non-metastatic, rectosigmoid carcinoma scheduled for elective colorectal surgery were studied. None of the patients was suffering from cardiac, hepatic, renal, or metabolic disorders or receiving medication. No subject had developed recent weight loss or had a plasma albumin concentration below 40 g/l.

Anesthesia. Anesthesia was induced with 2 mg/kg propofol; the trachea was intubated after administration of vecuronium bromide, 0.1 mg/kg, and the lungs were ventilated to normocapnia with oxygen-enriched air (FI^O2= 0.35). Nitrous oxide was not used in the study because it has the same molecular weight as carbon dioxide and thus interferes with the isotope ratio measurement of expired air¹³C-carbon dioxide. Continuous propofol infusion was maintained for 100 min at a rate of 120 [micro sign]g [middle dot] kg^-1[middle dot] min^-1as it provides plasma propofol concentrations between 2 and 6 [micro sign]g/ml, adequate for anesthesia without concomitant surgery. [9]Normal saline solution, 0.9%, was infused intravenously during the whole study period at a rate of 2 ml [middle dot] kg (^-1) [middle dot] h^-1. The degree of muscle relaxation was monitored using the train-of-four-ratio, and supplemental doses of vecuronium bromide were given to achieve complete muscle relaxation. Electrocardiography (ECG), noninvasive systemic arterial pressure, end-tidal concentrations of carbon dioxide, inspired concentration of oxygen, and oxygen saturation were monitored and recorded during anesthesia.

The patients were covered with a warming blanket to maintain normothermia. Core body temperature was measured with a thermocouple probe (Mono-a-therm, Mallinckrodt Medical Inc., St. Louis, MO) inserted in the aural canal and positioned adjacent to the tympanic membrane.

Measurement of Protein Kinetics. L-[1-(¹³) C]leucine (99% 1-(¹³) C) and sodium bicarbonate (99%¹³C) obtained from Cambridge Isotope Laboratories (Cambridge, MA) were prepared under sterile conditions in the hospital pharmacy. An aliquot of tracer was dissolved in a known volume of sterile water. The solution was passed through a 0.22-[micro sign]m filter into injection bottles. The bottles were sealed off, heat sterilized at 121 [degree sign]C for 15 min, and kept at 4 [degree sign]C until administration. Each set of solutions was confirmed to be free of pyrogens.

All patients were studied on the day of surgery at 8:00 AM after fasting 12 h overnight. A superficial vein in the dorsum of the hand was cannulated, and the cannula was kept patent with heparinized saline solution. A second superficial vein in the contralateral arm was cannulated to provide access for the infusion of L-[1-(¹³) C]leucine. Blood and expired air samples were collected before the infusion to determine baseline carbon-13 enrichment. Primed doses of¹³C-NaHCO³, 0.08 mg/kg, and L-[1-(¹³) C]leucine, 0.5 mg/kg, were administered and followed immediately by a continuous infusion of L-[1-(¹³) C]leucine, 0.008 mg [middle dot] kg^-1[middle dot] min^-1, which was maintained for 280 min. The tracer infusion rate was determined directly by weighing the tracer initially and at the end of the study. Five blood and expired air samples were collected after 3 h of isotope infusion and before the induction of anesthesia (baseline) and toward the end of propofol anesthesia, when the tracer was assumed to have reached an isotopic steady state. A schematic representation of the procedure is shown in Figure 1. Each blood sample collected before and during the isotope infusion was transferred immediately to a heparinized tube and centrifuged at 4 [degree sign]C. The plasma obtained was stored at -70 [degree sign]C until [1-(¹³) C] [Greek small letter alpha]-ketoisocaproate ([Greek small letter alpha]-KIC) enrichment was measured. Expired air samples were collected through a mouthpiece in a 2-1 latex bag and transferred immediately to 20-ml vacutainers to await¹³C-carbon dioxide isotope enrichment analysis. During artificial ventilation, expired gases were collected by means of a one-way valve into a 5-1 bag. Production of carbon dioxide (V^CO2) was measured by indirect calorimetry (Datex Deltatrac, Helsinki, Finland) over a 20-min period during plasma L-[1-(¹³) C]leucine steady state before and during anesthesia.

Protein Kinetics. Whole body leucine kinetics were calculated by conventional isotope dilution practice using a two-pool stochastic model during steady state conditions obtained at each phase of the studies. [14]Plasma enrichment of [Greek small letter alpha]-KIC was used as the basis for calculating flux and oxidation of leucine. [15]Thus, under steady state conditions, leucine flux (Q) is defined by the equation: Equation 1where S is the rate at which leucine is incorporated into body protein, O is the rate of oxidation of leucine, B is the rate at which unlabeled leucine enters the free amino acid pool from endogenous protein breakdown, and I is the rate of dietary intake or the rate of infusion of L-[1-(¹³) C]leucine ([micro sign]mol [middle dot] kg^-1[middle dot] h^-1), or both. Inspection of Equation 1indicates that when studies are conducted in the postabsorptive state, flux is equal to breakdown.

Plasma [Greek small letter alpha]-KIC enrichment was determined by positive chemical ionization gas chromatography-mass spectrometry as previously described. [16]Expired¹³C-carbon dioxide enrichment was analyzed by means of isotope ratio mass spectrometry and used to calculate leucine oxidation. A factor of 0.81 was applied to account for the fraction of¹³C-carbon dioxide released by¹³C-labeled leucine oxidation but retained within slow turnover rate pools of the body. [14]Enrichment of plasma [Greek small letter alpha]-KIC during infusion of L-[1-(¹³) C]leucine has been used to determine whole body leucine kinetics. This steady state reciprocal pool model is considered to represent the intracellular precursor pool enrichment more precisely than leucine itself. [17] 

Plasma Metabolites and Cortisol. Plasma concentration of glucose was measured by a glucose-oxidase method using a glucose analyzer 2 (Beckman Instruments, Fullerton, CA). Plasma lactate assay was based on lactate oxidase and was performed using the synchron CX 7 system (Beckman Instruments). The mean intraassay and interassay coefficients of variance were 3.0% and 4.5%, respectively.

Plasma concentration of non-esterified fatty acids (NEFA) was analyzed by using the Boehringer Mannheim enzymatic colorimetric kit (Boehringer Mannheim, Laval, Quebec, Canada). The mean intraassay and interassay coefficients of variance were 2.3% and 4.1%, respectively.

Circulating concentration of cortisol in plasma was measured using the Ciba Corning ACS 180 automated immunoassay (Ciba Corning Diagnostic Corp, East Walpole, MA). The mean intraassay and interassay coefficients of variance were 3.0% and 7.7%, respectively.

Calculation of power and patient number was based on the results of a previous study investigating the effect of general anesthesia with enflurane and surgery on protein metabolism. [8]Using Student paired t test and considering an expected mean change in protein flux: breakdown of 10% compared with baseline (power, 80%; [Greek small letter alpha] = 5.0), a total of six patients was calculated to be sufficient.

Data are presented as means (1 SD). Differences between whole body protein kinetics, i.e., protein flux: breakdown, protein oxidation and synthesis before and during anesthesia, were determined using the two-tailed Student paired t test. Analysis of variance with post hoc analysis by Student-Newman-Keuls test was used to examine within-group changes of hemodynamics and plasma concentrations of metabolic substrates and of cortisol. Statistical significance was accepted at P < 0.05.

Plateau enrichment for plasma [1-(¹³) C] [Greek small letter alpha]-KIC and expired¹³C-carbon dioxide was achieved in all infusions before and during anesthesia, and the mean coefficient of variation was 2.74% (SD, 1.13) and 3.95% (0.94), respectively. Figure 2illustrates the plateau enrichment of [1-(¹³) C] [Greek small letter alpha]-KIC and¹³C-carbon dioxide of one of the patients studied. Individual changes in protein metabolism are presented in Table 1. Propofol anesthesia caused a significant decrease of whole body protein breakdown by 6% (P < 0.05). In contrast, whole body leucine oxidation and protein synthesis showed no significant changes after 100 min of propofol administration.

Hemodynamic parameters and plasma concentrations of intermediary substrates and cortisol are shown in Table 2. No significant alterations of mean arterial pressure, heart rate, and oxygen saturation occurred during propofol infusion. Plasma concentrations of glucose and lactate also did not change significantly. The plasma concentrations of NEFA increased during propofol administration, but the changes were not significant. Plasma cortisol concentration significantly decreased during anesthesia, revealing statistical significance after 90 and 100 min of propofol infusion.

Baseline whole body carbon dioxide production at 159 ml/min (21) was not influenced by propofol (152 ml/min [28]). Mean baseline hematocrit was 39% (3) and 38% (4) during anesthesia. Baseline core temperature at 36.8 [degree sign]C (0.3) also remained unchanged after 100 min of propofol anesthesia (core temperature, 36.5 [degree sign]C [0.2]).

The present study showed that propofol anesthesia in humans does not significantly affect whole body protein synthesis and leucine oxidation, although it decreases protein flux:breakdown by a small but significant amount.

Although the impact of anesthesia combined with surgery on perioperative protein metabolism has been widely studied, the influence of anesthetics alone has received little attention. The majority of published studies have been focused on the metabolic effects of inhalational anesthetic agents. In lung, [18]liver, [19]and lymphocyte [20]preparations halothane has been shown to exhibit a dose-dependent and reversible depressive effect on fractional rate of protein synthesis. A progressive increase in protein breakdown and oxidation with increasing duration of anesthesia has been observed during isoflurane anesthesia in dogs. [6]A report on the metabolic consequences of halothane in dogs demonstrated that leucine oxidation and flux significantly increased after 180 min of anesthesia. [5]In contrast, 1 h of halothane anesthesia instituted after fentanyl premedication in patients undergoing cardiac surgery caused a decrease of leucine flux by 36%. [7]More recently, 1 h of enflurane anesthesia produced no significant alterations of whole body breakdown and protein synthesis in subjects before abdominal hysterectomy. [8] 

Intravenous anesthetics have been found to initiate negligible metabolic changes in humans. Modified neuroleptanesthesia using fentanyl and midazolam in the absence of surgery did not alter the flux of free amino acids across one leg [21]and muscle protein synthesis rate in patients undergoing cholecystectomy. [4] 

The results of these investigations using inhalation and intravenous anesthetics indicate that the effect of anesthesia on protein metabolism is variable and depends on the anesthetic agent used and the species studied.

The measurement of whole body protein turnover, protein synthesis, and oxidation gives a dynamic picture of the movement of proteins in the body compared with more conventional indicators of protein metabolism, such as nitrogen balance, or specific muscle degradation indicators, such as urinary 3-methylhistidine or creatinine. In the fasting state, the sole source of the essential amino acid leucine for protein synthesis and oxidation is that derived from the breakdown of endogenous proteins. To obtain an in vivo estimation of whole body protein metabolism, an isotope dilution technique has been applied infusing labeled L-[1-(¹³) C]leucine. [14]The flux of L-[1-(¹³) C]leucine represents the total movement of leucine into and from the plasma pool. Oxidation of leucine results in its conversion to¹³C-carbon dioxide. Therefore, leucine flux minus oxidation provides, indirectly, a measure of the rate of protein synthesis.

To achieve isotopic plateau conditions during anesthesia, we infused propofol for 100 min. It has been suggested that during the execution of tracer studies, at least 2 h should elapse before any observed establishment of a new isotopic plateau is interpreted as representing a real metabolic change. Studies reporting the effects of feeding or insulin therapy on leucine kinetics, [22,23]however, indicate that major metabolic events can be observed within 1 h, as reflected by changes in the tracer enrichment, although the final isotopic plateau was not obtained for approximately 2 h after the intervention. We are aware that the present results might not provide absolute proof that they truly reflect metabolic events occurring during this study. However, confidence that the results are valid is strengthened as the mean coefficient of variation of plateau values for expired¹³C-carbon dioxide and plasma [Greek small letter alpha]-KIC during propofol anesthesia was less than 4%.

Propofol infusion caused a minimal, although significant, decrease in whole body protein breakdown by 6%. This change appears to be of no clinical significance when compared with the 30-40% changes of protein breakdown observed in patients after colorectal surgery. [24,25]Whole body leucine oxidation decreased by 14% during propofol administration. Because of the large variability of data and the relatively few patients studied, this decrease in leucine oxidation did not reach statistical significance. Propofol anesthesia did not produce any significant alterations in plasma concentrations of glucose, lactate, and NEFA. This lack of influence of propofol on circulating metabolite concentrations is in agreement with the results of previous investigations involving inhalational anesthesia with enflurane, isoflurane, and halothane or intravenous anesthesia using fentanyl and midazolam of similar duration. [4,26,27] 

Propofol administration was associated with a significant decrease of cortisol plasma concentrations after 90 min of propofol anesthesia. Because a primary metabolic effect of cortisol in humans is stimulation of protein breakdown, the suppression of plasma cortisol levels might account for the decreased protein flux:breakdown observed in our patients. The decrease of plasma cortisol concentration cannot be explained by hemodilution because hematocrit remained unchanged during the study period. All patients were anesthetized during the mid-morning hours, therefore minimizing the impact of the circadian rhythm of cortisol metabolism. As the half-life of circulating cortisol is approximately 70-90 min, it is likely that the production of cortisol was decreased during the entire 100 min of propofol infusion. According to the results of in vitro studies, propofol at concentrations more than 20 [micro sign]g/ml significantly suppresses adrenocortical cortisol biosynthesis. [28]Propofol in this study was infused at a rate of 120 [micro sign]g [middle dot] kg^-1[middle dot] min^-1to achieve the plasma target concentration required for anesthesia without concomitant surgery at 2-6 [micro sign]g/l, [9]which is far lower than necessary to directly inhibit adrenal steroidogenesis. Studies investigating cortisol secretion during propofol anesthesia [29]and sedation in critically ill patients [30]concluded that although cortisol levels tend to decrease during the infusion period, there was no evidence of a clinically significant impairment of adrenal steroidogenesis. Thus, the decrease of plasma cortisol concentration in our study was rather the result of depressed body metabolism during propofol anesthesia than the result of a direct inhibition of adrenocortical cortisol biosynthesis. Similar decreases of cortisol plasma concentration have also been observed during the application of halothane and isoflurane in humans. [26] 

In summary, 100 min of propofol infusion applied at 120 [micro sign]g [middle dot] kg^-1[middle dot] min^-1decreased whole body protein breakdown without significantly altering whole body protein synthesis and oxidation in unpremedicated patients. The changes in whole body protein metabolism during propofol anesthesia were minimal and appear to be insignificant when compared with the metabolic response to surgery.

The authors thank T. Nordolillo for excellent technical assistance.